St. Joseph Health in Bryan, Texas, is addressing the increasing discussion surrounding weight management strategies, specifically comparing the apply of GLP-1 medications to bariatric surgery. The health system’s assessment comes as demand for GLP-1 drugs – including Ozempic, Wegovy and Mounjaro – continues to rise.
LeDoris Bowers, a Nurse Practitioner specializing in weight management at St. Joseph Health, emphasized the broader health benefits associated with these medications. “It’s the health benefit that patients get when they’re on it,” Bowers stated. “It’s known to help normalize your cholesterol, your blood pressure, stabilize your glucose levels, decent for your metabolic health, your hormonal health.”
Beyond these benefits, Bowers highlighted the positive impact GLP-1s can have on women experiencing perimenopause and postmenopause, and noted a demonstrated reduction in the risk of both heart attack and stroke among patients using the medications. According to Bowers, these medications are generally most appropriate for individuals with a Body Mass Index (BMI) between 27 and approximately 50.
For patients with a BMI of 45 or higher, Bowers indicated that bariatric surgery often demonstrates greater efficacy. She explained that she frequently prescribes GLP-1 medications to patients with BMIs in the 60s as a preliminary step to lower their BMI before considering surgical intervention. “The lower the BMI, the better the outcome,” she said.
St. Joseph Health maintains that the decision regarding whether to pursue GLP-1 medication or bariatric surgery is made on a case-by-case basis, tailored to the individual patient’s needs and health profile.
